brain ischemia market is Estimated to grow at a CAGR of 6.5% - Top Key Players- Bayer AG (Germany), H. Lundbeck A/S (Denmark), Bristol-Myers Squibb Company (US), Boehringer Ingelheim GmbH (Germany), ThromboGenics NV (Belgium), Vernalis Plc (UK), Neurotec

Brain ischemia is a medical condition in which there is lack of oxygen supply to the brain. This is due to narrowing of blood vesicles which is caused due to blood clot or other factors like cholesterol. Since last few years global brain ischemia market has been growing swiftly and is expected to grow at CAGR of 6.5 % from 2017 to2023. Due to increasing prevalence of cardiovascular diseases and other diseases which are affecting cardiovascular which is major factor that causes brain ischemia. Beside this adoption of sedentary lifestyle by the people across the globe has provided fuel for the growth of this market.

Geographically, global ischemia market is segmented into four major regions, North America, Europe, Asia Pacific plus Middle East and Africa. The worth of this market in 2016 was 1.43 billion and is expected to reach till 2023 billion by the end of 2023 by growing continuously at the CAGR of 6.5 %. North America contribute the highest share in the brain ischemic market. Due to increasing number of diabetic, obese and aging population in North America are major driving factor for the growth of this . Among all regions, ischemia’s market in Asia Pacific is the fastest growing market. . Due to a huge population and increasing prevalence of diseases like sickle cell anemia and diabetes in this region all these together has served to a platform for the growth of the market here.

Get a sample report at https://www.marketresearchfuture.com/sample_request/1424 .

Segmentation:

Global brain ischemia market is segmented on the basis of diagnosis which includes MRI, CT, ultrasound, angiography and other. The market is also segmented on the basis of treatment which includes angioplasty, drug treatment and other. Drug treatment is sub segmented into anticoagulation therapy, antiplatelet and other. Anticoagulation therapy is further sub segmented into heparin and warfarin. Antiplatelet therapy is further sub segmented as aspirin and other. On the basis of end user the market is segmented as hospital, clinics and other.

Competitive Analysis

Key player in the global brain ischemia market are Bayer AG (Germany), H. Lundbeck A/S (Denmark), Bristol-Myers Squibb Company (US), Boehringer Ingelheim GmbH (Germany), ThromboGenics NV (Belgium), Vernalis Plc (UK), Neurotec Pharma SL (Spain), Johnson and Johnson (US), Covidien Plc (Ireland), Stryker Corporation (US), Abbott Laboratories (US), Penumbra, Inc. (US), Philips Healthcare (Netherland), Hitachi Ltd. (Japan), GE Healthcare (UK) and Siemens Healthcare (US).

Due to increasing prevalence of many disease which causes brain ischemia; all these have attracted many multinational companies to develop their market in the global brain ischemia market. Companies are using the trend of strategic alliance and acquisition to gain a high position and minimize competition in the market

Bristol-Myers Squibb International which is headquartered in US; it s working on the trials of CV006-004, Acute Viprinex™ which are used for the treatment of brain ischemia.

A/S has presented a new effective and safe data for desmoteplase which is an thrombolytic drug used for the treatment of acute ischemic stroke. It has received fast-track designation from the U.S. Food and Drug Administration (FDA) for the treatment of acute ischemic stroke.

More inquire at https://www.marketresearchfuture.com/enquiry/1424 .

Stryker Corporation’s new drug “Trevo® Retriever” has show a remarkable results when used in the treatment of brain ischemia. This drug is the declared as a front-line treatment to reduce disability in ischemic stroke since last 20 years.

Penumbra, Inc. which is a medical device manufacturing company has launched the new MAX™ system reperfusion catheters for the treatment of acute ischemic stroke patients.

Boehringer Ingelheim GmbH a German headquartered company that has introduce Pradaxa® (dabigatran etexilate) an anticoagulant drug for the treatment of brain ischemia.

About us

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Market Research Future

P: +1 646 845 9312

W: www.marketresearchfuture.com

sales@marketresearchfuture.com

This release was published on openPR.